Company Oncotelic Therapeutics, Inc.

Equities

OTLC

US6283411097

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - OTC Markets Other stock markets 20:49:21 13/05/2024 BST			5-day change	1st Jan Change
0.0386 ^USD	+0.78%		+1.45%	+0.65%

04-12	Oncotelic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-25	Oncotelic Therapeutics, Inc. Announces Linkage of Cancer and Lupus in Gliomas Patients	CI

Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer. The Company has eight primary drug and AI technology programs: AL-101, an intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinsonâs Disease (PD), erectile dysfunction (ED) and female sexual dysfunction (FSD); CA4P, a vascular disrupting agent (VDA) in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma; Oxi4503, a second generation VDA for the treatment of liquid tumors with focus on childhood leukemia; OT-101, an antisense against TGF-Î²2 for the treatment of various cancers and viruses, including SARS and the COVID-19, and Artemisini, a natural derivative from an Asian herb Artemisia Annua that inhibits the ability of various viruses to multiply.

Number of employees: 22

USD in Million	2022	Weight	2023	Weight	Delta
Biopharmaceutical 100.0 %	0	nan %	0	100.0 %	-

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	0	nan %	0	100.0 %	-

Managers	Title	Age	Since
Vuong Trieu CEO	Chief Executive Officer	59	21/04/19
Amit Bhupendra Shah DFI	Director of Finance/CFO	57	30/06/19
Seymour H. Fein CTO	Chief Tech/Sci/R&D Officer	75	05/01/20
Anthony Maida CTO	Chief Tech/Sci/R&D Officer	59	10/05/20
Saran Saund PRN	Corporate Officer/Principal	66	31/10/19

Members of the board	Title	Age	Since
Steven King BRD	Director/Board Member	59	10/05/20
Anthony Maida CTO	Chief Tech/Sci/R&D Officer	59	10/05/20
Vuong Trieu CEO	Chief Executive Officer	59	21/04/19

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	398,664,555	179,523,741 ( 45.03 %)	0	45.03 %

Name	Equities	%	Valuation
Vuong Trieu 24.75 %	98,916,746	24.75 %	4 M $
Balaji Bhakta 10.42 %	41,630,811	10.42 %	2 M $
Larn Hwang 5.869 %	23,455,990	5.869 %	961 696 $
Hsiao Chao 4.272 %	17,073,604	4.272 %	700 018 $
Autotelic, Inc. 4.198 %	16,780,384	4.198 %	687 996 $
Saran Saund 4.117 %	16,456,480	4.117 %	674 716 $
Steven King 0.8333 %	3,330,647	0.8333 %	136 557 $
Anthony Maida 0.2846 %	1,137,314	0.2846 %	46 630 $
Amit Bhupendra Shah 0.0898 %	358,837	0.0898 %	14 712 $
GAM London Ltd. 0.000104 %	416	0.000104 %	17 $

Oncotelic Therapeutics, Inc.

29397 Agoura Road Suite 107

91301, Agoura Hills

http://www.oncotelic.com

address Oncotelic Therapeutics, Inc.(OTLC)

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
ONCOTELIC THERAPEUTICS, INC.	+0.65%	15.29M
VERTEX PHARMACEUTICALS INCORPORATED	+5.66%	109B
REGENERON PHARMACEUTICALS, INC.	+11.23%	105B
ARGENX SE	-0.38%	22.25B
BIONTECH SE	-12.15%	22.09B
GENMAB A/S	-7.66%	18.68B
WUXI APPTEC CO., LTD.	-36.52%	17.58B
BEIGENE, LTD.	-10.09%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.33%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.58%	12.46B

Bio Therapeutic Drugs